Study to Evaluate the Pharmacokinetics (PK), Safety and Tolerability up to 6 Years of Intravenous (i.v.) Secukinumab in Pediatric Participants With Juvenile Psoriatic Arthritis (JPsA).
Recruiting now · Phase 1
Conditions studied: Juvenile Psoriatic Arthritis
In brief
The purpose of this study is to determine the PK, safety and tolerability of multiple doses of intravenous (i.v.) secukinumab in pediatric participants with JPsA
Key facts
- Study ID
- NCT06751238
- Run by
- Novartis Pharmaceuticals
- People needed
- 20
- Starts
- 2025-09-24
- Expected to finish
- 2032-12-01
- Last updated by the study team
- 2026-07-10
Who can join
Age: 2 and older, up to 17. Sex: any. Healthy volunteers: not accepted.
Where it is running
- University of Florida — Gainesville, Florida, United States (enrolling)
- Ann and Robert H Lurie Childs Hosp — Chicago, Illinois, United States (enrolling)
- Levine Childrens Hospital — Charlotte, North Carolina, United States (enrolling)
- Cincinnati Childrens Hospital — Cincinnati, Ohio, United States (enrolling)
- Univ Hosp Cleveland Medical Center — Cleveland, Ohio, United States (enrolling)
- Legacy Emanuel Research Hosp Portland — Portland, Oregon, United States (enrolling)
- Childrens Hosp Pittsburgh UPMC — Pittsburgh, Pennsylvania, United States (enrolling)
- Texas Arthritis Center — El Paso, Texas, United States (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.